The retina is a thin layer of light-sensitive tissue located at the back of the eye. It converts light into electrical signals that are transmitted to the brain, allowing vision. In dogs affected by prcd-PRA, a mutation in the PRCD gene (Progressive Rod-Cone Degeneration gene) causes gradual dysfunction and death of photoreceptor cells. This degeneration typically begins with rod cells and later affects cone cells, leading to a stepwise loss of vision.
Clinical signs of prcd-PRA usually develop in adulthood, although timing can vary depending on breed. The earliest symptom is often night blindness, where dogs struggle to see in dim light or darkness. Owners may notice hesitation when moving in low-light environments, reluctance to go outside at night, or bumping into objects in poorly lit areas. As the disease progresses, daytime vision becomes affected, resulting in difficulty navigating familiar surroundings, misjudging distances, and reduced ability to track moving objects.
Eventually, prcd-PRA leads to complete blindness. Despite this, the condition is not painful, and many dogs adapt well to vision loss by relying on their other senses, such as smell and hearing. With proper environmental management, affected dogs can continue to live comfortable and active lives.
The prcd-PRA DNA Health Test is designed to detect the specific mutation in the PRCD gene responsible for this form of Progressive Retinal Atrophy. Testing is simple, safe, and non-invasive, typically performed using a cheek swab or blood sample. The sample is analyzed in a specialized laboratory to determine the dog’s genetic status. Because DNA does not change throughout life, testing can be performed at any age, including in puppies before symptoms appear.
Results are generally reported in three categories:
- Clear (Normal): The dog does not carry the prcd-PRA mutation and cannot pass it to offspring.
- Carrier: The dog carries one copy of the mutation but is typically unaffected during its lifetime. However, it can pass the mutation to future generations.
- Affected/At Risk: The dog carries two copies of the mutation and is highly likely to develop Progressive Retinal Atrophy (prcd-PRA) and experience gradual vision loss.
Genetic testing for prcd-PRA is extremely valuable for breeders, veterinarians, and dog owners. Breeders can use results to make informed mating decisions that help eliminate the mutation from breeding populations while maintaining healthy genetic diversity. Avoiding carrier-to-carrier breeding significantly reduces the risk of producing affected puppies.
For dog owners, knowing a dog’s genetic status allows for early planning and management of vision loss. Dogs identified as at risk can benefit from environmental adjustments such as maintaining consistent furniture placement, using verbal cues, and providing safe, obstacle-free spaces. Routine veterinary eye examinations can also help monitor progression. While there is currently no cure for prcd-PRA, supportive care can significantly improve quality of life.
The Progressive Retinal Atrophy (prcd-PRA) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine ocular health, and helps reduce the impact of this inherited retinal degeneration in future generations.
